Forming a network of clinicians and scientists

The Nordic AML Group (NAMLG) aim to foster excellence in research and clinical care in acute myeloid leukemia (AML) in the Nordic countries, by forming an active network of clinicians and basic and translational scientists with deep interest and experience in the field.

Photo: NASA

MRD webinar – 2023-10-10

Measurable residual disease (MRD) is an important prognostic factor during the course of AML, but how do we use it in clinical practices and how can MRD guide treatment choices and risk-adapted therapy?

The NAMLG Educational Working Group arranges a webinar on MRD on 2023-10-10, 15:30-17:30 CEST.

Register for the webinar via this link.

Click here for the programme and more information.

Medicinske Tidsskrifter has applied for and obtained sponsorship support from Jazz Pharmaceutical to complete the webinar.

Nordic AML Meeting

24-25 August, 2023, Bergen, Norway

Raddison Blu Bryggen, Bergen

See final program

Why a Nordic AML Group?

Recognizeable systems in Nordic countries, similar treatment traditions, one working market.

Unmet need to improve AML therapy through research and clinical trials.